Merrimack Pharmaceuticals' Series G Brings in $77M
By Catherine Shaffer
Monday, April 18, 2011
Merrimack Pharmaceuticals Inc. raised $77 million in a Series G to finance its full house of five clinical-stage cancer candidates, plus a trio of preclinical candidates and multiple research-stage programs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.